Efficacy and safety of iloprost in patients with septic shock-induced endotheliopathy-Protocol for the multicenter randomized, placebo-controlled, blinded, investigator-initiated trial

Morten H Bestle, Niels E Clausen, Peter Søe-Jensen, Klaus T Kristiansen, Theis Lange, Pär I Johansson, Jakob Stensballe, Anders Perner, Morten H Bestle, Niels E Clausen, Peter Søe-Jensen, Klaus T Kristiansen, Theis Lange, Pär I Johansson, Jakob Stensballe, Anders Perner

Abstract

Background: In Europe 700.000 new cases of sepsis occur annually and more than 100.000 of these patients die due to multiorgan failure (MOF). We have identified shock-induced endotheliopathy (SHINE) to be associated with development of MOF and mortality. Furthermore, in patients with septic shock those with circulating levels of thrombomodulin (TM) above 10 ng/mL have twice the mortality (56% vs 28%) than those with levels below this level. Pilot studies indicate that infusion of iloprost (1 ng/kg/min) is associated with improved endothelial function in patients with septic shock.

Material and methods: This is a multicenter, randomized, blinded, investigator-initiated, adaptive phase 2B trial in up to 384 patients with septic shock-induced endotheliopathy defined by TM > 10 ng/mL who are allocated 1:1 to 72 hours continuous infusion of iloprost 1 ng/kg/min or placebo (equal volume of saline). The primary outcome is the mean daily modified Sequential Organ Failure Assessment (SOFA) score in the ICU up to day 90. Secondary outcomes include 28- and 90-day all-cause mortality, days alive without vasopressor in the ICU within 90 days, days alive without mechanical ventilation in the ICU within 90 days, days alive without renal replacement therapy in the ICU within 90 days, numbers of serious adverse reactions, and the number of serious adverse events within the first 7 days.

Discussion: This trial tests the safety and efficacy of iloprost vs placebo for 72 hours in patients with septic shock and SHINE. The outcome measures focus on the potential effect of the intervention to mitigate organ failure.

Trial registration: COMBAT-SHINE trial-EudraCT no. 2019-001131-31-Clinicaltrials.gov: NCT04123444-Ethics Committee no. H-19018258.

Keywords: clinical trial; iloprost; septic shock-induced endotheliopathy; thrombomodulin.

Conflict of interest statement

Dr PJ is co‐inventor of a patent covering the use of iloprost for the treatment of SHINE and the use of TM as a diagnostic biomarker here.

© 2020 The Authors. Acta Anaesthesiologica Scandinavica published by John Wiley & Sons Ltd on behalf of Acta Anaesthesiologica Scandinavica Foundation.

References

    1. Suarez De La Rica A, Gilsanz F, Maseda E. Epidemiologic trends of sepsis in western countries. Ann Transl Med. 2016;4:325.
    1. Reinhart K, Daniels R, Kissoon N, et al. Recognizing sepsis as a global health priority. N Engl J Med. 2017;377:414‐417.
    1. Angus DC, van der Poll T. Severe sepsis and septic shock. N Engl J Med. 2013;369:840‐851.
    1. Kaukonen K‐M, Bailey M, Suzuki S, Pilcher D, Bellomo R. Mortality related to severe sepsis and septic shock among critically ill patients in Australia and New Zealand, 2000–2012. JAMA. 2014;311:1308‐1316.
    1. Holst LB, Haase N, Wetterslev J, et al. Lower versus higher hemoglobin threshold for transfusion in septic shock. N Engl Med. 2014;371:1381‐1391.
    1. Opal SM, Dellinger RP, Vincent J‐L, Masur H, Angus DC. The next generation of sepsis clinical trial designs: what is next after the demise of recombinant human activated protein C? Crit Care Med. 2014;42:1714‐1721.
    1. Johansen M, Johansson P, Ostrowski S, et al. Profound endothelial damage predicts impending organ failure and death in sepsis. Semin Thromb Hemost. 2015;41:16‐25.
    1. Ostrowski SR, Gaïni S, Pedersen C, Johansson PI. Sympathoadrenal activation and endothelial damage in patients with varying degrees of acute infectious disease: an observational study. J Crit Care. 2015;30:90‐96.
    1. Johansson PI, Haase N, Perner A, Ostrowski SR. Association between sympathoadrenal activation, fibrinolysis, and endothelial damage in septic patients: a prospective study. J Crit Care. 2014;29:327‐333.
    1. Johansson PI, Stensballe J, Ostrowski SR. Shock induced endotheliopathy (SHINE) in acute critical illness – a unifying pathophysiologic mechanism. Crit Care. 2017;21:25.
    1. Moncada S, Gryglewski R, Bunting S, et al. An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation. Nature. 1976;263:663‐665.
    1. Rubin LJ, Groves BM, Reeves JT, Frosolono M, Handel F, Cato AE. Prostacyclin‐induced acute pulmonary vasodilation in primary pulmonary hypertension. Circulation. 1982;66:334‐338.
    1. Windeløv NA, Ostrowski SR, Perner A, Johansson PI. Transfusion requirements and clinical outcome in intensive care patients receiving continuous renal replacement therapy: comparison of prostacyclin vs. heparin prefilter administration. Blood Coagul Fibrinolys. 2010;21:414‐419.
    1. Bruggeman LA, Pellicoro JA, Horigan EA, Klotman PE. Thromboxane and prostacyclin differentially regulate murine extracellular matrix gene expression. Kidney Inter. 1993;43:1219‐1225.
    1. Sussmann M, Sarbia M, Meyer‐Kirchrath J, Nüsing RM, Schrör K, Fischer JW. Induction of hyaluronic acid synthase 2 (HAS2) in human vascular smooth muscle cells by vasodilatory prostaglandins. Circ Res. 2004;94:592‐600.
    1. Kawabe J, Yuhki K, Okada M, et al. Prostaglandin I2 promotes recruitment of endothelial progenitor cells and limits vascular remodeling. Arterioscler Thromb Vasc Biol. 2010;30:464‐470.
    1. Birukova AA, Tian Y, Dubrovskyi O, et al. VE‐cadherin trans‐interactions modulate Rac activation and enhancement of lung endothelial barrier by iloprost. J Cell Physiol. 2012;227:3405‐3416.
    1. Chen HH, Chen TW, Lin H. Prostacyclin‐induced peroxisome proliferator‐activated receptor‐alpha translocation attenuates NF‐kappaB and TNF‐alpha activation after renal ischemia‐reperfusion injury. Am J Physiol Renal Physiol. 2009;297:F1109‐1118.
    1. Cheng C‐F, Lian W‐S, Chen S‐H, et al. Protective effects of adiponectin against renal ischemia‐reperfusion injury via prostacyclin‐PPARα‐heme oxygenase‐1 signaling pathway. J Cell Physiol. 2012;227:239‐2499.
    1. Holmvang L, Ostrowski SR, Dridi NP, Johansson P. A single center, open, randomized study investigating the clinical safety and the endothelial modulating effects of a prostacyclin analog in combination with eptifibatide in patients having undergone primary percutaneous coronary intervention (PCI) for ST‐segment elevation myocardial infarction. Prostaglandins Other Lipid Mediat. 2012;99:87‐95.
    1. Johansson PI, Mortensen CR, Nielsen T, et al. The effect of intraoperative and 6‐h postoperative intravenous administration of low‐dose prostacyclin on the endothelium, hemostasis, and hemodynamics in patients undergoing a pancreaticoduodenoctemy: a randomized‐controlled pilot study. Eur J Gastroenterol Hepatol. 2017;29:400‐406.
    1. Berthelsen RE, Ostrowski SR, Bestle MH, Johansson PI. Co‐administration of iloprost and eptifibatide in septic shock (CO‐ILEPSS)‐a randomised, controlled, double‐blind investigator‐initiated trial investigating safety and efficacy. Crit Care. 2019;23:301.
    1. Schulz KF, Altman DG, Mother D. CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. J Pharmacol Pharmacother. 2010;1:100‐107.
    1. Gordon AC, Perkins GD, Singer M, et al. Levosimendan for the prevention of acute organ dysfunction in sepsis. N Engl J Med. 2016;375:1638‐1648.
    1. Taichman DB, Sahni P, Pinborg A, et al. Data sharing statements for clinical trials: a requirement of the International Committee of Medical Journal Editors. Lancet. 2017;389:e12‐e14.
    1. Grant SM, Iloprost GKL. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in peripheral vascular disease, myocardial ischaemia and extracorporeal circulation procedures. Drugs. 1992;43:889‐924.
    1. Singer M, Deutschman CS, Seymour CW, et al. The third international consensus definitions for sepsis and septic shock (sepsis‐3). JAMA. 2016;315:801‐810.
    1. Dellinger RP, Levy MM, Rhodes A, et al. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2012. Crit Care Med. 2013;41:580‐637.

Source: PubMed

Sponsorzy i współpracownicy

Warunki medyczne

Interwencje lekowe

3
Subskrybuj